Business Cooperation
Home Partnerships

Leveraging our expertise in the field of protein-protein interactions, we are developing an innovative pipeline featuring small molecule candidates that target apoptotic pathways, as well as next-generation tyrosine kinase inhibitors with first- and best-in-class potential. We are committed to partnering with other complementary organizations that share our vision of bringing meaningful cures to patients with various cancers, hepatitis B, and age-related diseases.

Our current partners are listed below.

  • University of Michigan

    Ascentage’s long-term R&D collaboration with U of M, gives the Company access to more than 40 scientists under the leadership of Dr. Shaomeng Wang—Ascentage co-founder, CSO and renowned researcher in the field of protein-protein interactions. Product candidates licensed to Ascentage from Dr. Wang's lab include AT-101, APG-115, APG-1252, and APG-1387. 

  • Unity Biotechnology

    In April 2016, Ascentage announced a strategic worldwide collaboration with UNITY Biotechnology to develop senolytic treatments designed to halt or reverse the aging process in several age-related diseases. In preclinical studies, UNITY—which is backed by ARCH Venture Partners, Venrock and Wuxi Healthcare Ventures—has demonstrated that clearing senescent cells reverses or prevents many age-related diseases including osteoarthritis, atherosclerosis, glaucoma, and kidney disease.

    As part of the deal, UNITY gained access to Ascentage’s compound library, which have shown promise in clearing senescent cells. Though specific terms were undisclosed, the companies agreed to form a joint venture for the development and commercialization of senolytic drugs in China.  

  • Merck & Co., Inc.

    In 2013, Ascentage in-licensed APG-8361 (formerly HQP-8361) from Merck for exclusive rights in the Asia Pacific region, including Japan. APG-8361 is a highly selective and potent c-Met inhibitor with a strong safety profile.